新赣江 — Investor Relations & Filings
About 新赣江
Jiangxi Xinganjiang Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of a diverse range of pharmaceutical products. The company's portfolio encompasses chemical active pharmaceutical ingredients (APIs), chemical drug preparations, and traditional Chinese medicine (TCM) formulations. Its core product offerings target therapeutic areas such as cardiovascular and cerebrovascular health, digestive system disorders, and nutritional supplementation. Key products include Ginkgo Biloba extract, Vitamin C, and various gastrointestinal medications. By maintaining an integrated value chain that spans from raw material synthesis to finished dosage forms, the company ensures quality control and supply chain efficiency. It focuses on delivering high-quality healthcare solutions through continuous innovation in pharmaceutical manufacturing and formulation technology.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 2026年第一次临时股东会决议公告 | 2026-04-20 | Chinese | |
| 财通证券股份有限公司关于江西新赣江药业股份有限公司2025年度持续督导跟踪报告 | 2026-04-20 | Chinese | |
| 财通证券股份有限公司关于江西新赣江药业股份有限公司2025年度持续督导定期现场检查报告 | 2026-04-19 | Chinese | |
| 2025年度独立董事述职报告(石美金) | 2026-04-14 | Chinese | |
| 财通证券股份有限公司关于江西新赣江药业股份有限公司2025年度募集资金存放及使用情况的专项核查报告 | 2026-04-14 | Chinese | |
| 第三届董事会第十九次会议决议公告 | 2026-04-14 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 40134517 | 2026年第一次临时股东会决议公告 | 2026-04-20 | Chinese | ||
| 40134504 | 财通证券股份有限公司关于江西新赣江药业股份有限公司2025年度持续督导跟踪报告 | 2026-04-20 | Chinese | ||
| 40134491 | 财通证券股份有限公司关于江西新赣江药业股份有限公司2025年度持续督导定期现场检查报告 | 2026-04-19 | Chinese | ||
| 40134475 | 2025年度独立董事述职报告(石美金) | 2026-04-14 | Chinese | ||
| 40134463 | 财通证券股份有限公司关于江西新赣江药业股份有限公司2025年度募集资金存放及使用情况的专项核查报告 | 2026-04-14 | Chinese | ||
| 34904183 | 第三届董事会第十九次会议决议公告 | 2026-04-14 | Chinese | ||
| 34904169 | 关于召开2025年年度股东会通知公告(提供网络投票) | 2026-04-14 | Chinese | ||
| 34904157 | 董事、高级管理人员薪酬管理制度 | 2026-04-14 | Chinese | ||
| 34904144 | 2025年度内部控制自我评价报告 | 2026-04-14 | Chinese | ||
| 34904120 | 内部控制审计报告 | 2026-04-14 | Chinese | ||
| 34898157 | 审计委员会对会计师事务所2025年度履职情况评估报告 | 2026-04-14 | Chinese | ||
| 34898136 | 2025年度募集资金存放、管理与实际使用情况的鉴证报告 | 2026-04-14 | Chinese | ||
| 34898067 | 2025年度募集资金存放、管理与实际使用情况的专项报告 | 2026-04-14 | Chinese | ||
| 34898049 | 2025年年度报告摘要 | 2026-04-14 | Chinese | ||
| 34898014 | 2025年年度报告 | 2026-04-14 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
新赣江 via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58812/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58812 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58812 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58812 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58812}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for 新赣江 (id: 58812)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.